Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab-Reference-Cited by-同舟云学术

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab

Published:2016-11-11 Issue:21 Volume:8 Page:35289-35300
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Toledo Rodrigo A.¹²,Cubillo Antonio¹³,Vega Estela¹³,Garralda Elena¹³,Alvarez Rafael¹³,de la Varga Lisardo U.¹³,Pascual Jesús R.¹³,Sánchez Gema¹²,Sarno Francesca¹²,Prieto Susana H.⁴,Perea Sofía¹²,Lopéz-Casas Pedro P.²,López-Ríos Fernando⁴,Hidalgo Manuel²⁵

Affiliation:

1. Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain

2. Spanish National Cancer Research Centre (CNIO), Madrid, Spain

3. Universidad San Pablo CEU, Madrid, Spain

4. Laboratorio de Dianas Terapeúticas, Madrid, Spain

5. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review;Journal of Personalized Medicine;2024-07-15

2. A panorama of colon cancer in the era of liquid biopsy;The Journal of Liquid Biopsy;2024-06

3. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road;Frontiers in Pharmacology;2024-04-22

4. The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study;British Journal of Cancer;2023-07-24

5. Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer;Clinical Cancer Research;2023-07-12